Overview
The Future of Clinical Trials is Decentralised.
During the pandemic, decentralised clinical trials became more and more relevant. With moving away from on-site trials, this new trend changes the reality of big and complex data management, the use of artificial intelligence tools and new regulatory frameworks. How do we manage gathering, storage and processing of data in a decentralised environment? The community still discusses the full application of CTIS and the regulatory application.
At the Clinical Trials and Data Science Conference, decision-makers across the industry, regulatory and patient organisations will meet to discuss the future of clinical trials to find innovative solutions.
Key Topics
- Decentralised Clinical Trials
- Use of Data Science in Clinical Trials
- Updates on the EMA/HMA Big Data Taskforce
- DARWIN EU
- Data Protection and Security
- Artificial Intelligence Regulatory Frameworks: Impact on Pharma
- IMI Initiatives
- European Health Data Space (EHDS)
- RWE
Why should you attend this conference?
Featured
Program Committee
-
Álmath Máire Spooner, PhD, RPh • Chair
EFPIA IEGU working group, Belgium -
Daniel Millar, MBA • Senior Director, Strategic Business Transformation
Janssen Research & Development, United States -
Elke Stahl, PhD • Senior Expert, Clinical Trials Department
Federal Institute For Drugs and Medical Devices (BfArM), Germany -
Jesper Kjær, MS • Co-Chair, EMA/HMA Big Data Steering Group; Director of Data Analytics Centre
Danish Medicines Agency (DKMA), Denmark -
Patrick Brady, PharmD • Head Regulatory Policy & Intelligence
Bayer AG / Research & Development, Pharmaceuticals, Germany -
Joyce Swart • Clinical Disclosure Lead
Alcon Research, LLC, United States -
Nick Sykes, MS • Senior Director, Global Regulatory Affairs
Pfizer Inc, United Kingdom -
Ruediger Pankow, DrSc • Regulatory Affairs Expert, CTIS Project Owner
Germany -
Fia Westerholm, DVM, MSc • Programme Assurance Manager
European Medicines Agency, Netherlands